High-Dose IV Vitamin C Therapy in Ireland: Evidence and Cost

Vitamin C taken by mouth is absorbed through a limited set of transporters in the gut, and once the blood reaches a certain concentration, usually a modest multiple of normal levels, the kidneys simply excrete the surplus. That ceiling means no amount of oral supplementation can push plasma vitamin C much above roughly 200 to 280 micromoles per litre, regardless of the dose swallowed.

Intravenous administration bypasses that gut bottleneck entirely, delivering vitamin C directly into the bloodstream and allowing plasma concentrations tens of times higher than oral intake can achieve. This is the entire rationale behind high-dose IV vitamin C therapy: it is pursuing a pharmacological effect that is simply not available through diet or oral supplements, using doses that can range from a few grams up to 25, 50, or even higher numbers of grams per infusion, delivered over one to several hours depending on the dose.

This is also why high-dose IV vitamin C should be thought of as a different intervention from a standard vitamin drip or Myers cocktail, which typically contains only a gram or two of vitamin C alongside B vitamins and minerals. The two are often offered at the same clinics, but they are not interchangeable in either their dose, their intended effect, or their risk profile.

A systematic review published in the Journal of Medicine and Life in January 2026 pulled together the strongest available evidence on high-dose intravenous vitamin C, searching PubMed, Scopus, and Web of Science from 2010 to 2025 and prioritising randomised controlled trials and systematic reviews. The reviewers found that high-dose IVC has plausible physiological effects through antioxidant activity, a role in catecholamine production, and immune modulation, including evidence from experimental sepsis research of down-regulation of certain pro-inflammatory signalling pathways.

In oncology specifically, phase I and II clinical studies demonstrated that high-dose IV vitamin C is generally well tolerated and associated with quality-of-life improvements when used alongside standard chemotherapy, not as a replacement for it. One randomised phase II trial in metastatic pancreatic cancer, combining IV vitamin C with chemotherapy, reported a promising survival signal in that specific trial, in that specific cancer type, in patients already receiving standard treatment.

Crucially, the same review concluded that the evidence does not support routine use of high-dose IV vitamin C in sepsis, despite earlier interest in the approach. This is exactly the kind of honest, condition-by-condition distinction that matters: the same intervention can show a signal worth investigating in one setting and show no supporting evidence in another, and conflating the two does a disservice to anyone trying to make an informed decision.

It is worth being precise about what the oncology data does and does not show, because this is where IV vitamin C is most actively marketed and most easily oversold. The studies described in the 2026 review are phase I and II trials, meaning they are primarily designed to establish safety, tolerability, and early signals of benefit in a small number of patients, not phase III trials with the statistical power to confirm a survival benefit definitively.

The pancreatic cancer trial that reported a promising survival signal did so in patients with metastatic disease who were also receiving gemcitabine and nab-paclitaxel, standard chemotherapy agents. The IV vitamin C was tested as an addition to that chemotherapy, not as a stand-alone treatment, and the trial's own design reflects that it is investigating an adjunct, not an alternative to oncology care.

No responsible reading of this evidence supports using high-dose IV vitamin C instead of chemotherapy, radiotherapy, surgery, or any other treatment a patient's oncology team recommends. Where it has shown a signal, it has done so as a supportive addition within a conventional treatment plan, under medical supervision, in a clinical trial setting. Anyone considering it for a cancer diagnosis should discuss it directly with their treating oncologist, not substitute a wellness clinic's advice for that conversation.

The most serious documented risk of high-dose IV vitamin C is haemolysis, the breakdown of red blood cells, in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic condition that leaves red blood cells vulnerable to oxidative stress. A 2022 meta-summary in the Indian Journal of Critical Care Medicine reviewed 14 published case reports of vitamin C-induced haemolysis spanning doses from 1 to 200 grams per day, finding that just over 71% of the affected patients had G6PD deficiency, and that half of these cases involved additional complications including acute kidney injury, disseminated intravascular coagulation, or methemoglobinemia.

The same case review found that the majority of complications appeared within three days of starting vitamin C, and that intravenous formulations accounted for just over half of the reported cases, with the rest involving very high oral doses. One death was recorded among the fourteen cases reviewed, underscoring that this is a genuine, if uncommon, risk rather than a theoretical one.

The 2026 systematic review echoed this, flagging oxalate nephropathy, a form of kidney injury from vitamin C's breakdown product oxalate, as a second major risk alongside G6PD-related haemolysis, with both risks rising at very large or repeated doses. This is precisely why a responsible clinic will not administer a high dose without first screening for G6PD deficiency and taking a kidney health history, and anyone who has not been screened should ask about this before their first session.

People with known or suspected G6PD deficiency should not receive high-dose IV vitamin C without specialist medical input, given the haemolysis risk documented above. People with a history of kidney stones, chronic kidney disease, or reduced kidney function should also be cautious, since the kidneys are responsible for clearing the oxalate that high-dose vitamin C produces as it is metabolised, and impaired kidney function increases the risk of oxalate-related injury.

People on warfarin or other blood thinners should discuss IV vitamin C with their prescribing doctor first, as high doses can interact with anticoagulation monitoring. Pregnant or breastfeeding women should also seek medical advice before undergoing high-dose infusions, since the safety data in this population specifically is limited.

Reputable Irish clinics should carry out a health questionnaire, and ideally a G6PD screening test for anyone considering doses above a few grams, before a first infusion. If a clinic offers a 25 gram or larger dose without asking about your G6PD status or kidney history, that is a reasonable basis for choosing a different provider.

Pricing for high-dose IV vitamin C in Ireland varies substantially by dose, reflecting both the cost of the vitamin C itself at higher quantities and the longer nursing time required to administer it safely. A session typically costs between €120 and €350, with lower doses in the few-gram range sitting at the bottom of that range and doses of 25 grams or more, which require slower infusion to avoid discomfort and osmotic side effects, sitting closer to the top.

Infusion time scales with dose. A standard vitamin drip containing a gram or two of vitamin C alongside other nutrients might take 30 to 45 minutes, while a genuinely high-dose infusion of 25 grams or more commonly takes one to three hours, because vitamin C must be delivered slowly to avoid vein irritation and to let the kidneys keep pace with the osmotic load.

Prices last checked October 2026; these figures will vary between clinics depending on the exact dose offered, whether blood tests or G6PD screening are included in the price, and whether the session is delivered in-clinic or as part of a mobile IV service.

Vitamin C itself is not a prescription-only medicine, but intravenous administration of any substance is a clinical procedure that should be carried out by an appropriately trained doctor or registered nurse, not a beautician or unregulated practitioner. Several IV vitamin and mineral products used in Irish hospitals, such as high-potency intravenous vitamin preparations used to treat deficiency, are themselves authorised medicines regulated by the Health Products Regulatory Authority, which maintains a public register of every medicine licensed for use in Ireland.

Standalone wellness clinics offering high-dose IV vitamin C sit outside the hospital system, but the same basic safety principle applies: a qualified clinician should take a relevant medical history, including kidney function and any known blood disorders, before administering a high dose, and should be present or readily available throughout the infusion in case of an adverse reaction.

Anyone booking a session should ask directly who will be administering it and what screening, if any, happens beforehand. A clinic that cannot answer those two questions clearly is not one that should be trusted with a needle and a vein.

High-dose IV vitamin C sits in a genuinely interesting, still-developing part of the evidence base. It is not the cancer cure or all-purpose immune booster it is sometimes marketed as, and the 2026 systematic review was explicit that its role in sepsis is not supported and its role in oncology remains supportive and exploratory rather than established. At the same time, it is not snake oil either: the oncology quality-of-life data and the mechanistic rationale for reaching plasma concentrations unavailable through oral dosing are real, published findings from legitimate peer-reviewed research.

For most people considering it for general wellness, immune support, or recovery from illness, the honest summary is that it is reasonably well tolerated at moderate doses in people without G6PD deficiency or kidney problems, carries a small but real risk of harm in those who have not been screened, and lacks strong trial evidence of benefit for most of the conditions it is marketed for outside of oncology and specific research settings.

Anyone with a cancer diagnosis, kidney disease, or a family history of blood disorders should talk to their own doctor before trying it, rather than relying on a wellness clinic's marketing material. For everyone else, it is a reasonable, moderate-risk option to try, provided the clinic screens properly and the dose is sensible, but it should be understood as a wellness intervention with an interesting research story behind it, not a medical treatment with a single, well-established clinical outcome attached to it.